BioMarin Pharmaceutical Inc. (LON:0HNC)
London · Delayed Price · Currency is GBP · Price in USD 53.91
+0.90 (1.70%)
At close: Sep 16, 2025
BioMarin Pharmaceutical Market Cap
BioMarin Pharmaceutical has a market cap or net worth of 7.64 billion as of September 18, 2025. Its market cap has decreased by -42.18% in one year.
Market Cap
7.64B
Enterprise Value
7.04B
Revenue
2.24B
Ranking
n/a
PE Ratio
15.93
Stock Price
53.91
Market Cap Chart
Since July 23, 1999, BioMarin Pharmaceutical's market cap has increased from 283.77M to 7.64B, an increase of 2,592.88%. That is a compound annual growth rate of 13.41%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 16, 2025 | 7.59B | -24.15% |
| Dec 31, 2024 | 10.01B | -29.83% |
| Dec 29, 2023 | 14.26B | -10.67% |
| Dec 30, 2022 | 15.96B | 33.26% |
| Dec 31, 2021 | 11.98B | 2.74% |
| Dec 31, 2020 | 11.66B | 1.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 177.00B |
| GSK plc | 59.54B |
| Haleon | 31.92B |
| Smith & Nephew | 12.02B |
| ConvaTec Group | 4.70B |
| Hikma Pharmaceuticals | 3.56B |
| HUTCHMED (China) | 2.15B |
| Genus | 1.65B |